000165728 001__ 165728
000165728 005__ 20260113234335.0
000165728 0248_ $$2sideral$$a147129
000165728 037__ $$aART-2024-147129
000165728 041__ $$aeng
000165728 100__ $$aClusa, Laura
000165728 245__ $$aAntimicrobial activity and potential of Olive leaf extract as a topical agent to combat Staphylococcus aureus and MRSA strains: an in vitro evaluation
000165728 260__ $$c2024
000165728 5060_ $$aAccess copy available to the general public$$fUnrestricted
000165728 5203_ $$aBackground: Staphylococcus aureus is one of the most prevalent bacteria in skin and soft tissue infections (SSTIs). Multidrug-resistant strain emergence, particularly methicillin-resistant S. aureus (MRSA), highlights the need for alternative treatments. Objectives: This study investigates the antimicrobial properties of olive leaf extract (OLE) and describes an epidemiological profiling of patients with SSTI who may benefit from it. Methods: OLE was tested in two reference strains, methicillin-susceptible S. aureus (MSSA) ATCC 29213 and MRSA ATCC 700699, and in 126 clinical isolates from patients with SSTIs according to Clinical Laboratory Standards Institute guidelines. Results: The minimum bactericidal concentration (MBC) ranged from 3.12% to 6.25% w/v for MSSA and 1.56% to 3.12% for MRSA. The lethal curve showed a reduction of 6 log10CFU/mL after two hours of incubation. Most of the 126 clinical samples (103 MSSA and 23 MRSA) came from skin lesions, surgical wounds, and ulcers. Over 90% of MSSA strains were resistant to less than five antibiotics, while 82% of MRSA strains were resistant to more than six. Penicillins demonstrated the lowest susceptibility rate (19.8%), whereas linezolid, daptomycin, pristinamycin, trimethoprim–sulfamethoxazole, teicoplanin, vancomycin, and OLE exhibited 100% susceptibility. No growth was observed for all clinical strains with OLE at ≥6.25% w/v. Conclusions: The findings suggest that OLE could become a promising alternative treatment for skin infections, particularly in the context of increasing antibiotic resistance.
000165728 536__ $$9info:eu-repo/grantAgreement/ES/CIBERObn/CB06-03-1012$$9info:eu-repo/grantAgreement/ES/DGA/B10-23R$$9info:eu-repo/grantAgreement/ES/DGA/B16-23R$$9info:eu-repo/grantAgreement/ES/DGA/B59-23D$$9info:eu-repo/grantAgreement/ES/MICINN-AEI/PRTR-C17.I1$$9info:eu-repo/grantAgreement/ES/MCINN/PID2022-136414OB-I00
000165728 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000165728 590__ $$a4.8$$b2024
000165728 591__ $$aPHARMACOLOGY & PHARMACY$$b51 / 352 = 0.145$$c2024$$dQ1$$eT1
000165728 591__ $$aCHEMISTRY, MEDICINAL$$b18 / 72 = 0.25$$c2024$$dQ1$$eT1
000165728 592__ $$a1.019$$b2024
000165728 593__ $$aDrug Discovery$$c2024$$dQ1
000165728 593__ $$aPharmaceutical Science$$c2024$$dQ1
000165728 593__ $$aMolecular Medicine$$c2024$$dQ2
000165728 594__ $$a7.7$$b2024
000165728 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000165728 700__ $$aLatorre-Millán, Miriam
000165728 700__ $$aMilagro, Ana María
000165728 700__ $$aTristancho-Baró, Alexander
000165728 700__ $$aLopez-Calleja, Ana Isabel
000165728 700__ $$0(orcid)0000-0002-9582-5472$$aGarcía-Lechuz, Juan Manuel
000165728 700__ $$aFortuño, Blanca
000165728 700__ $$aVillar, Nuno del
000165728 700__ $$aAsensio, Mario
000165728 700__ $$aMartín-Belloso, Olga
000165728 700__ $$aOdriozola-Serrano, Isabel
000165728 700__ $$0(orcid)0000-0002-8100-5596$$aMartínez-Beamonte Roberto$$uUniversidad de Zaragoza
000165728 700__ $$0(orcid)0000-0002-8251-8457$$aOsada, Jesús$$uUniversidad de Zaragoza
000165728 700__ $$0(orcid)0000-0001-7294-245X$$aRezusta, Antonio
000165728 700__ $$0(orcid)0000-0001-8034-3617$$aGilaberte, Yolanda$$uUniversidad de Zaragoza
000165728 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000165728 7102_ $$11002$$2050$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Biología Celular
000165728 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000165728 773__ $$g18, 9 (2024), 1358 [18 pp.]$$pPharmaceuticals$$tPharmaceuticals$$x1424-8247
000165728 8564_ $$s1601105$$uhttps://zaguan.unizar.es/record/165728/files/texto_completo.pdf$$yVersión publicada
000165728 8564_ $$s2758185$$uhttps://zaguan.unizar.es/record/165728/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000165728 909CO $$ooai:zaguan.unizar.es:165728$$particulos$$pdriver
000165728 951__ $$a2026-01-13-22:07:01
000165728 980__ $$aARTICLE